Wu C T, Pei X T, Cao J R, Xue H H
Department of Experimental Hematology, Beijing Institute of Radiation Medicine, People's Republic of China.
Leuk Res. 1993 Jul;17(7):557-60. doi: 10.1016/0145-2126(93)90084-x.
DBP possesses a new pharmacological activity leading to selective deterioration of leukemic cells, with less harmful effect on the growth of normal hematopoietic progenitors.
DBP具有一种新的药理活性,可导致白血病细胞选择性退化,对正常造血祖细胞的生长危害较小。